Clinical trials: SARS-CoV-2 Virus Infection
Covid19, Paludism
Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)
In this study, the investigators will explore the reasons for the apparently lower proportion of severe COVID-19 cases in many sub-Sahara African countries.
- Trial name
- Palu-COVID (NCT05012280)
- Where
- Democratic Republic of the Congo
- Volunteers
- 238 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Covid19, Pregnancy Related
Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19
Pregnant women are a vulnerable and high-risk population, as COVID-19 is associated with an increased risk preterm birth, cesarean section, and maternal critical care.
- Conditions
- Covid19, Pregnancy Related, Maternal Complication of Pregnancy, Coronavirus
- Trial name
- STOPCOVID19 (NCT04718220)
- Testing
- Antibody testing for SARS-CoV-2 IgG, Testing for SARS-CoV-2 RNA, Testing for SARS-CoV-2 IgM/IgG
- Where
- United States
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
SARS CoV 2 Infection
Using Vibroacoustic Therapy in a Patient With Co-infection and COVID-19
This article describes a case of successful treatment of a 59-year-old man with sepsis as a result of periprosthetic infection against the background of severe SARS-CoV-2-19, who was hospitalized for 59 days, 57 of which were in…
- Trial name
- NCT05188482
- Testing
- vibroacoustic therapy
- Where
- Kazakhstan
- Volunteers
- 1 people
- Sponsor
- Astana Medical University
COVID-19, Myocardial Injury
Myocardial Injury and Quality of Life After COVID-19
In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis Post Infection
- Trial name
- NCT04794062
- Where
- Russia
- Volunteers
- 119 people
- Sponsor
- Voronezh Regional Clinical Consultative and Diagnostic Center
SARS CoV 2 Infection, Alveolar; Injury
The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19
COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the…
- Conditions
- SARS CoV 2 Infection, Alveolar; Injury, Children, Pneumonia, Viral
- Trial name
- NCT05619640
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Haseki Training and Research Hospital
Coronavirus Disease 2019
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
The investigators conducted a single-center, open-label, parallel-group randomized controlled trial to assess the efficacy and safety of a Chinese herb compound granule Huashi Baidu granule (HSBDG) in pediatric patients with…
- Trial name
- NCT05501288
- Testing
- Huashi Baidu granule, compound pholcodine oral solution
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shanghai Children's Medical Center
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
COVID-19, Vaccines
Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile
Phase 2 clinical trial in adults previously vaccinated against SARS-CoV-2 in Chile with an initial schedule of two doses of CoronaVac® plus two booster doses with different vaccines.
- Trial name
- CoronaVarCL (NCT05593042)
- Testing
- CoronaVac®, Omicron Vaccine, Trivalent Vaccine
- Where
- 3 sites in Chile
- Volunteers
- 551 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Infection Viral, Infection, Hospital
Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF
The COVID-19 pandemic of SARS CoV2 (Severe Acute Respiratory Syndrome, COVID-19) infection, which is currently evolving in France, raises many questions about the clinical and biological profile of infected hospitalized patients.
- Conditions
- Infection Viral, Infection, Hospital, COVID
- Trial name
- CCF (NCT04344327)
- Where
- 23 sites in France
- Volunteers
- 2,878 people
- Sponsor
- French Cardiology Society
SARS-CoV-2
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation…
- Trial name
- NCT05894525
- Where
- Japan
- Volunteers
- 8,844 people
- Sponsor
- ModernaTX, Inc.
Multiple Osteochondroma, Osteogenesis Imperfecta
Resilience and Coping in a Rare Skeletal Disease Population to Face Coronavirus (COVID-19) Outbreak Distress: a Longitudinal Study
In the COVID-19 outbreak context, people living with rare diseases have been highly troubled with anxiety, loneliness, and depression.
- Conditions
- Multiple Osteochondroma, Osteogenesis Imperfecta, Ollier Disease, Maffucci Syndrome
- Trial name
- RELOAD (NCT04844697)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Istituto Ortopedico Rizzoli
SARS-CoV Infection, Interferon
The Containing Coronavirus Disease 19 (COVID-19) Trial
In recent months severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has emerged as a novel human pathogen and, susceptibility amongst humans is presumed to be universal.
- Conditions
- SARS-CoV Infection, Interferon, Covid19
- Trial name
- ConCorD-19 (NCT04552379)
- Testing
- Peginterferon beta-1a
- Where
- Chile
- Volunteers
- 1,173 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
COVID-19, SARS-CoV-2
FREEDOM COVID-19 Anticoagulation Strategy
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era.
- Trial name
- FREEDOM COVID (NCT04512079)
- Testing
- Enoxaparin, Apixaban
- Where
- 21 sites in United States, Brazil and 3 more
- Volunteers
- 3,460 people
- Sponsor
- Valentin Fuster
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Sars-CoV2, Innate Immunity
Immune Cells Phenotypes During COVID-19
The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%.
- Conditions
- Sars-CoV2, Innate Immunity, Immunization; Infection, Alveolar Lung Disease
- Trial name
- IMMUNO-COVID (NCT04816760)
- Testing
- Peripheral blood samples
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Hospitalo-Universitaire Méditerranée Infection
Covid19
Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts
Many uncertainties remain regarding the epidemiological and clinical characteristics of COVID-19, including the number of people exposed to the disease, the persistence of the humoral response and its associated neutralisation…
- Trial name
- COVID-SeroPRIM (NCT04808986)
- Testing
- Serological test for the detection of IgG anti-SARS-CoV-2
- Where
- France
- Volunteers
- 2,817 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
COVID-19
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination…
- Trial name
- NCT05193279
- Testing
- Candidate vaccine, SCB-2019
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19
Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults
This is a randomized, double-blind, parallel-controlled, equivalence trial, for evaluation of safety and immunogenicity, and batch-to-batch consistency of a recombinant adenovirus type-5-vectored Covid-19 vaccine Convidecia in…
- Trial name
- NCT05313646
- Testing
- batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV
- Where
- China
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
COVID-19 PrEP HCW HCQ Study
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04354870
- Testing
- Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.